Glucagon-like peptide-1 (GLP-1) and Gastric inhibitory polypeptide (GIP) while Ozempic (Semaglutide) only targets GLP-1.

Stock analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of Iovance Biotherapeutics in a ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...

The document outlines various health-related news, including a measles outbreak in Texas and New Mexico, UNICEF's aid crisis ...

Researchers at Indiana University and Wuhan University in China have unveiled a groundbreaking chemical process that could streamline the development of pharmaceutical compounds, chemical building ...

Iovance Biotherapeutics (NASDAQ: IOVA) is a biotech company with an innovative approach to developing cancer medicines. Here's what investors need to know about this small-cap biotech company. Iovance ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

Talks of a trade dispute between the United States and Australia over the cost of medicines have no doubt left many ...

One of the biggest hurdles in the sugar and ethanol industries is strict government regulations on wastewater management, ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.

Soliman said consumers could see price increases or shortages of generic drugs in the country. There are some laws that ...